Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation

被引:45
作者
Hansen, JR
Roehm, PC
Chatterjee, P
Green, SH
机构
[1] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA
关键词
acoustic neuroma; cell proliferation; cell culture; ErbB2; Schwann cell; trastuzumab;
D O I
10.1002/glia.20316
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Vestibular schwannomas (VSs) are benign tumors that arise from the Schwann cells (SCs) lining the vestibular nerve. VS cells survive and proliferate far from neurons and axonally derived growth factors. We have previously shown that VSs produce the glial growth factor, neuregulin-1 (NRG1), and its receptors, ErbB2 and ErbB3. In the present work, we explore the contribution of constitutive NRG1:ErbB signaling to human VS cell proliferation. We confirm that human VSs, which express markers of immature and denervated SCs, also express endogenous NRG1 and activated ErbB2. We find that a blocking anti-NRG1 antibody and trastuzumab (Hereptin (R), HCN), a humanized anti-ErbB2 inhibitory monoclonal antibody, effectively inhibit NRG1 induced SC proliferation. Treatment of primary VS cultures with anti-NRG1 or HCN reduces cell proliferation in the absence of exogenous NRG1. Furthermore, conditioned medium from VS cell cultures contains NRG1 and stimulates SC proliferation in SC cultures, an effect that is inhibited by anti-NRG1 and HCN. These data suggest an autocrine pathway of VS growth stimulation involving NRG and ErbB receptors. Inhibition of constitutive NRG:ErbB signaling reduces VS cell proliferation in vitro and may have therapeutic potential for patients with VSs. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:593 / 600
页数:8
相关论文
共 66 条
  • [1] Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO
  • [2] 2-2
  • [3] Proliferation of human Schwann cells induced by neu differentiation factor isoforms
    Baek, SY
    Kim, SU
    [J]. DEVELOPMENTAL NEUROSCIENCE, 1998, 20 (06) : 512 - 517
  • [4] MUTATIONS IN TRANSCRIPT ISOFORMS OF THE NEUROFIBROMATOSIS-2 GENE IN MULTIPLE HUMAN TUMOR TYPES
    BIANCHI, AB
    HARA, T
    RAMESH, V
    GAO, JZ
    KLEINSZANTO, AJP
    MORIN, F
    MENON, AG
    TROFATTER, JA
    GUSELLA, JF
    SEIZINGER, BR
    KLEY, N
    [J]. NATURE GENETICS, 1994, 6 (02) : 185 - 192
  • [5] GERMLINE MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 TUMOR-SUPPRESSOR GENE
    BOURN, D
    CARTER, SA
    MASON, S
    EVANS, DGR
    STRACHAN, T
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (05) : 813 - 816
  • [6] GLIAL GROWTH-FACTOR LIKE ACTIVITY IN SCHWANN-CELL TUMORS
    BROCKES, JP
    BREAKEFIELD, XO
    MARTUZA, RL
    [J]. ANNALS OF NEUROLOGY, 1986, 20 (03) : 317 - 322
  • [7] Cardillo MR, 1999, AM J OTOL, V20, P65
  • [8] Carroll SL, 1997, J NEUROSCI, V17, P1642
  • [9] MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation
    Chadee, DN
    Kyriakis, JM
    [J]. NATURE CELL BIOLOGY, 2004, 6 (08) : 770 - 776
  • [10] Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway
    Cunnick, JM
    Dorsey, JF
    Standley, T
    Turkson, J
    Kraker, AJ
    Fry, DW
    Jove, R
    Wu, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) : 14468 - 14475